the lead drug in Elpiscience’s bispecific macrophage engager (BiME) pipeline. Astellas has licensed rights to ES019 and a second unnamed programme and has also taken an option on up to two ...

Building on grounding-breaking research into the immuno-suppressive role of tumor-associated macrophages (TAMs), Macomics has developed a unique platform, ENIGMAC combining a human bioinformatic ...

The alliance is intended to develop and commercialise the multi-specific macrophage engager NM49 in the oncology field. "Ono Pharmaceutical partners with EME for antibody drug discovery" was ...